Satellite Press Releases and News

RIDGEFIELD, Conn., and INDIANAPOLIS, Nov. 13, 2016 /PRNewswire/ — New data presented today at the American Heart Association Scientific Sessions 2016 showed that Jardiance® (empagliflozin) tablets consistently reduced the risk for cardiovascular death, regardless of the type of cardiovascular disease at baseline, compared with placebo when added to standard of care in adults with type 2 diabetes and established cardiovascular disease. The findings are part of the landmark EMPA-REG OUTCOME® trial, which is the first trial of a diabetes medication to show a reduction in cardiovascular death in adults with type 2 diabetes and established cardiovascular disease. This study is supported by Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY).

“Cardiovascular disease is two to four times more common in people with type 2 diabetes and is an umbrella term consisting of several different vascular outcomes, including heart attack, heart failure,

... read more at: http://satprnews.com/page/608/

by